معرفی
Catherine Larson-Nath is an Associate Professor in the Department of Pediatric Gastroenterology, Hepatology & Nutrition at the University of Minnesota Medical School. Her clinical and research work focuses on pediatric intestinal failure, Alagille syndrome, and related liver and nutritional disorders.
Research Interests: Dr. Larson-Nath's expertise spans pediatric gastroenterology, hepatology, and clinical nutrition. Her research emphasizes the natural history of Alagille syndrome, intestinal failure management, catheter-related infections, body composition assessment, and nutritional interventions in children with complex liver and gastrointestinal diseases. She is particularly involved in rare disease research and international cohort studies.
Recent Research Trends: Her most recent publications (2023–2025) focus on the long-term outcomes of maralixibat treatment in Alagille syndrome, catheter salvage in pediatric intestinal failure, and the impact of genetic and non-genetic factors on disease expression. These works reflect a strong commitment to improving clinical care through evidence-based, patient-centered research.
Scientific Contributions:
- Principal Investigator (PI) of the Intestinal Failure Registry funded by The Transplantation Society.
- PI of The Global Alagille Alliance (GALA) Study, a major international research initiative.
- Co-Investigator on the NIH-funded SMART Bottle STTR Phase II project.
Advising and Grants: Dr. Larson-Nath leads multiple funded research projects, including international collaborations and NIH-supported studies. She actively contributes to advancing clinical guidelines and has been cited in policy documents and clinical practice sources. While no formal advisees are listed, her leadership in multicenter studies indicates significant mentorship and team coordination.
Labs and Teams: She is a key member of multidisciplinary teams focused on pediatric liver disease and intestinal rehabilitation, collaborating with surgeons, nutritionists, and geneticists. Her work with the GALA study group highlights her leadership in global rare disease research networks.
